GlassScriptPhysician profile
Steven Adams
NPI 1174847198
$1,880.95
in general payments reported to CMS, 2019-2025
21 companies · $50.81 in 2025
The $50.81 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $156 · 2021: $491 · 2022: $441 · 2023: $383 · 2024: $169 · 2025: $50.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $602.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $905.32 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Astellas Pharma US INC | $269.01 | 2019-2025 | Veozah |
| Hologic Sales and Service, LLC | $92.24 | 2020-2023 | Coolseal Generator |
| Exeltis, USA INC. | $88.10 | 2022-2025 | Slynd |
| Amgen INC. | $81.60 | 2020-2022 | |
| Shield Therapeutics INC | $71.85 | 2023-2024 | Accrufer |
| Merck Sharp & Dohme LLC | $55.63 | 2020-2021 | |
| Lilly USA, LLC | $39.74 | 2020-2023 | Emgality, Reyvow |
| Biohaven Pharmaceutical Holding Company LTD. | $36.67 | 2022 | |
| Scynexis, INC. | $36.67 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $36.63 | 2021 | |
| Boston Scientific Corporation | $27.25 | 2023 | Watchman Flx |
| Aspira Women'S Health INC | $22.64 | 2023 | Ova1 |
| Pfizer INC. | $19.55 | 2023 | |
| Novo Nordisk INC | $19.54 | 2024 | Rybelsus |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $15.61 | 2021 | |
| Axonics, INC. | $15.04 | 2023 | Bulkamid |
| Daiichi Sankyo INC. | $13.36 | 2024 | Injectafer |
| Roche Diagnostics Corporation | $11.82 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.54 | 2019 | |
| Lupin INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.